3rd CMI-PB Prediction Challenge

1st Informational Session September 6th, 2024

La Jolla Institute for Immunology



Background and Benefits of Prediction Challenges



- Quantitative and unbiased evaluation of model performance
- Drives participants to strive for accuracy and outperform their other participants
- Encourages a wide range of participants to join
- Contributes to a deeper understanding of the topic at hand



16th Community Wide Experiment on the Critical Assessment of Techniques for Protein Structure Prediction



Obstacles in developing computational models for biological applications



- Systems vaccinology studies have:
 - Varying study designs
 - Multi-dimensional and heterogeneous data
 - Many parameters and few study participants
 - A lack of methods to test the generalizability and predictive performance of models objectively
- Accounting for <u>variability between individuals</u> is necessary to ensure the robustness and accuracy of computational models
- It is important to capture <u>temporal dynamics</u> in system vaccinology models

Our Approach:

- To establish a community platform to develop and test computational models of immunity in vaccination
- To better understand vaccine-induced immunity to *B. pertussis*



Agenda for Today's Session





Presentation Agenda

1.	2.		3.	4.		5.
Introduction- Project Overview	The CMI-PB Challenge	-	Example Model Presentation	Resources Overview	_	Q & A



Pertussis (Whooping Cough)



Sources: Centers for Disease Control, World Health Organization, PLOS Medicine, PubMed

Waning Immunity from aP pertussis vaccination



- 1940s: Introduction of an inactivated <u>whole bacteria PT</u> vaccine (wP) dramatically decreased cases
- 1995: Vaccine-related side effects led to a replacement with the <u>a</u>cellular <u>P</u>T vaccine (**aP**) in the USA
- aP induced protection wanes faster than wP → Why?

Reported NNDSS pertussis cases: 1922-2021



Source: National Notifiable Diseases Surveillance System, CDC

Recruitment Strategy





Characterizing immune responses - Multiomics approach





- PBMC cell frequencies by flow cytometry
 - Total of 37 distinct cell populations



Plasma antigen-specific antibody titers by Luminex

- Antibody Isotypes: IgG, IgG1, IgG2, IgG3, IgG4
- Vaccine Antigens
 - Pertussis Toxin (PT), PRN, FHA, FIM2/3
 - Tetanus Toxoids (TT), Diphtheria Toxoids (DT), OVA (irrelevant control)



- Plasma proteomics by Olink & Legendplex
 - Concentration of 48 cytokines



PBMC Transcriptomics by bulk RNA-Seq



- Antigen-specific T cell responses by AIM assay & FluoroSpot
 - Magnitude of CD4⁺ T cell activation (% OX40⁺CD25⁺ CD4⁺ T cells)
 - Cytokine polarization (IFN-γ, IL-5 and IL-17)

Databases, Model building, and Prediction Challenge





Providing access to experimental data in a standardized format



Find more information on the website here



Presentation Agenda





	Annual prediction	Contestants	Number of subjects		Current status
	challenge title		Training dataset	Challenge dataset	
1	First Challenge: Internal dry run	CMI-PB consortium	60 (28 aP + 32 wP)	36 (19 aP + 17 wP)	Concluded in May 2022
2	Second Challenge: Invited challenge	Invited contestants	96 (47 aP + 49 wP)	21 (11 aP + 10 wP)	Concluded in January 2024
3	Third Challenge: Open Challenge	Public	117 (58 aP + 59 wP)	54 (27 aP + 27 wP)	Announced on August 27 2024

B. Prediction challenge outline





CMI-PB Vaccines Response Prediction Challenge: Overview

C. Overview of the CMI-PB Challenge data





The data is split into two groups:

- **Training dataset (2020, 2021, 2022)**: Used to build models, including known outcomes ("ground truth"). Features are based on multi-omics readouts and demographic data, with potential for feature engineering.
- **Challenge dataset (2023)**: Used to evaluate model performance on unseen data. The task is to predict vaccine response outcomes without provided ground truth.

Challenge related information and Data access is provided via the CMI-PB website

C. CMI-PB Challenge Data: Raw and Processed Data



- The dataset comprises three multi-omics datasets (from 2020, 2021, and 2022) and the challenge dataset (2023).
- The data require careful processing and normalization to generate computable matrices suitable for model development.
- While data processing and normalization approaches can vary depending on user preferences, the CMI-PB team has provided a standardized data processing method inspired by the approach used in the 2nd CMI-PB challenge.
- Pipeline: <u>RPub</u> and <u>GitHub</u>



Data Access: https://www.cmi-pb.org/downloads/cmipb_challenge_datasets/current/3rd_challenge/

D. Prediction tasks for CMI-PB Challenge

- Previously identified <u>vaccine responses</u> are formulated as prediction tasks
- General vaccine responses:
 - <u>Plasma IgG levels</u> increased at <u>day 14</u> <u>post-booster</u> vaccination compared to baseline
 - Increase in the percentage of <u>monocytes</u> on day 1 post-booster than baseline
- aP/wP specific vaccine responses:
 - A subset of <u>aP-primed individuals</u> showed an increased expression of proinflammatory genes, including <u>CCL3</u> <u>at day 3</u> post-booster vaccination



A system-view of *Bordetella pertussis* booster vaccine responses in adults primed with whole-cell versus acellular vaccine in infancy

Ricardo da Silva Antunes, ... , Alessandro Sette, Bjoern Peters

JCI Insight. 2021;6(7):e141023. https://doi.org/10.1172/jci.insight.141023.

Monocytes lgG.PT 20 013 14 30 90 Days post boost Davs post boost aP wΡ CCL3 PM Days post boost

D. Prediction tasks for CMI-PB Challenge



List of tasks

				-				
1) Antibody titer tasks								
1.1) Rank the individuals by IgG antibody titers agair	nst pertussis toxir	n (PT) that we dete	ct in plasma 14 days	predicted values				
post booster vaccinations.	0.5	20.407 - 202 - L	551 401					
1.2) Rank the individuals by fold change of IgG antib	ody titers agains	t pertussis toxin (P	T) that we detect in	predicted fo	ld-change			
plasma 14 days post booster vaccinations compared	I to titer values at	day 0.		values	la onlango			
 2) Cell frequencies tasks 2.1) Rank the individuals by predicted frequency of M 2.2) Rank the individuals by fold change of predicted vaccination compared to cell frequency values at day 3) Gene expression tasks 3.1) Rank the individuals by predicted gene expression 	Monocytes on day I frequency of Mo y 0. ion of CCL3 on d	y 1 post boost after mocytes on day 1 p ay 3 post-booster v	vaccination. bost booster raccination.	Ī	Example of Ra	ankings		
3.2) Rank the individuals by fold change of predicted	SubjectID	BaselineVal	Post-VacVal	FoldChangeVal	RankPost-VacVa	RankFoldChangeVal		
vaccination compared to gene expression values at								
	119	2.9	6.7	2.31	2	3		
	119 120	2.9 5.1	6.7 8.7	2.31 1.71	2	3		
The ultimate goal is to model	119 120 121	2.9 5.1 1.2	6.7 8.7 3.5	2.31 1.71 2.92	2 1 6	3 4 1		
The ultimate goal is to model as many of the tasks as	119 120 121 122	2.9 5.1 1.2 4.5	6.7 8.7 3.5 5.1	2.31 1.71 2.92 1.13	2 1 6 4	3 4 1 5		
The ultimate goal is to model as many of the tasks as possible. However, contestants are not required to submit	119 120 121 122 123	2.9 5.1 1.2 4.5 4.7	6.7 8.7 3.5 5.1 4.8	2.31 1.71 2.92 1.13 1.02	2 1 6 4 5	3 4 1 5 6		
The ultimate goal is to model as many of the tasks as possible. However, contestants are not required to submit answers for all tasks.	119 120 121 122 123 124	2.9 5.1 1.2 4.5 4.7 2.7	6.7 8.7 3.5 5.1 4.8 6.5	2.31 1.71 2.92 1.13 1.02 2.41	2 1 6 4 5 3	3 4 1 5 6 2		

E. Submission File



SubjectID /	Age BiologicalSexAtBirth	VaccinePrimingStatus	1.1) IgG-PT-D14-titer-Rank	1.2) IgG-PT-D14-FC-Rank	2.1) Monocytes-D1-Rank	2.2) Monocytes-D1-FC-Rank	3.1) CCL3-D3-Rank	3.2) CCL3-D3-FC-Rank
119	23 Female	aP	32	43	10	52	ç	28
120	27 Female	WP	33	37	13	21	44	25
121	22 Female	aP	14	2	32	15	7	34
122	23 Female	aP	26	19	9	45	37	6
123	26 Female	WP	22	54	46	49	2	15
124	22 Male	aP	35	25	53	44	16	i 10
125	29 Male	WP	36	17	38	23	36	43
126	29 Male	WP	7	23	23	20	6	21
127	26 Female	aP	28	50	2	47	26	24
128	28 Female	WP	48	46	21	2	20	50
129	31 Male	WP	53	52	4	31	3	14
130	26 Male	WP	29	8	39	8	45	33
131	24 Female	aP	43	44	1	29	34	49
132	27 Male	WP	45	5	19	4	40	17
133	25 Female	aP	17	33	37	10	47	20
134	32 Male	WP	31	41	41	16	22	46
135	27 Male	WP	50	51	16	19	28	13
136	27 Female	WP	30	7	47	1	50	54
137	24 Female	aP	39	9	28	38	52	37
138	22 Male	aP	16	10	24	51	25	8
139	29 Female	WP	24	21	3	28	38	22

A submission file with entries for **all tasks**

SubjectID A	ge BiologicalSexAtBirth	VaccinePrimingStatus	1.1) IgG-PT-D14-titer-Rank 1.2) IgG-PT-D14-FC-Rank	2.1) Monocytes-D1-Rank	2.2) Monocytes-D1-FC-Rank	3.1) CCL3-D3-Rank 3.2) CCL3-D3-FC-Rank
119	23 Female	aP	17			19
120	27 Female	WP	46			43
121	22 Female	aP	10			11
122	23 Female	aP	30			6
123	26 Female	WP	44			30
124	22 Male	aP	20			54
125	29 Male	WP	13			41
126	29 Male	WP	11			10
127	26 Female	aP	25			51
128	28 Female	WP	53			4
129	31 Male	WP	36			8
130	26 Male	WP	41			29
131	24 Female	aP	34			39
132	27 Male	WP	22			9
133	25 Female	aP	21			40
134	32 Male	WP	7			53
135	27 Male	WP	51			24
136	27 Female	WP	4			52
137	24 Female	aP	32			18
138	22 Male	aP	23			13
130	20 Eemale	WD	50			37

A submission file with entries for two tasks

Populated with random numbers. Submission file template is available on website.

F. Model Evaluation and Scoring











* If you have a blank cell (or put NA) in your submission, we will replace that cell with the median rank of that list

Spearman

correlation

Step 2/2 Point systems Task winner: 8 points 98% confidence interval: 6 points significant: 1 point Max per task: 8 points Max all tasks: 48 points

Challenge scoring

* You cannot receive a combination of these points (ie. 8 + 1)

Find the detailed information regarding Prizes on the website here.

d. Overview of the CMI-PB Challenge data





Challenge related information and Data access is provided via the CMI-PB website

F. Evaluation: Prizes & Awards



Prize Details:

- If there is a tie for first place, the prizes for first and second place will be combined and split equally among the winning teams. There will be no separate second-place prize awarded, and the team originally in second-place will receive the third place prize. The team originally in third place will not receive a prize.
 - In the event of multiple teams tying for first place, the prizes for first, second, and third place will be combined and split equally among all the winning first-place teams. No separate second or third-place prizes will be awarded.
 - If there is a tie for second place, the prizes for second and third place will be combined and split equally between the tied teams. The original third-place team will not receive a prize. This applies if there are multiple teams tied for second place.
 - In the case of a tie for third place, only the prize for third place will be shared equally between the tied teams.

Find more information on the website <u>here</u>.

- All submitters with at least one significant score will be acknowledged as co-authors in the manuscript written following this challenge.
- Additionally, prizes will be awarded to the top three teams with the best-performing models. The total money prize is \$5000.
 - 1st place: \$3000
 - 2nd place: \$1500
 - 3rd place: \$500



G. Prediction challenge outline





CMI-PB Vaccines Response Prediction Challenge: Overview



Presentation Agenda



A. Models from First (internal) challenge





32 models were developed during the first challenge by three teams:

- **Team 1:** Establishing baseline prediction models from the systems vaccinology literature
- **Team 2:** Establishing purpose-built models using Joint and Individual Variation Explained (JIVE)
- **Team 3:** Establishing purpose-built models using Multiple Co-Inertia Analysis (MCIA)

Link to paper here

B. Models from Second (invited) challenge



biorxiv The preprint server for Biology						
Pramod Shinde (Author) Author Area	Submit	Submission History	Help	FAQ	Feedback	Log Out
Manuscripts Undergoing Screening The manuscript below has entered the screening process. Click on the links below	the manu	script metadata to perf	orm ac	ctions.		
BIORXIV/2024/611290						
Putting computational models of immunity to the test - an invited challer	ige to pre	dict B. pertussis vac	cinati	on ou	tcomes	
Pramod Shinde ២, Lisa Willemsen, Michael Anderson, Minori Aoki, Saonli Basu	厄 , Julie (G Burel ២, Peng Cher	ng, So	uradip	to Ghosh D)astidar,
Aidan Dunleavy, Tal Einav, Jamie Forschmiedt, Slim Fourati, Javier Garcia, Willian	۱ Gibson, Ja	ason A Greenbaum, Ley	ying G	uan, V	Veikang Gu	an,
Jeremy P Gygi, Brendan Ha, Joe Hou, Jason Hsiao, Yunda Huang, Rick Jansen, Bł Konstorum, Jiyeun Lee, Sloan A Lewis, Aixin Li, Eric F Lock, Jarjapu Mahita, Marc Orfield, James Overton, Nidhi Pai, Cokie Parker, Brian Qian, Mikkel Rasmussen, Jo	argob Kako us Mendes, paquin Rey	oty, Zhiyu Kang, James , Hailong Meng, Aidan № na, Eve Richardson, Sa	; J Kob Veher, ndra S	ie 🕩 Soma Safo, J	, Mari Kojiı yeh Nili, Sh osey Soren	ma, Anna ielby son,
Aparna Srinivasan, Nicky Thrupp, Rashmi Tippalagama, Raphael Trevizani, Steffe Grant, Steven H Kleinstein, and Bjoern Peters	n Ventz, Jiu	ızhou Wang, Cheng-Ch	ang W	u, Fer	hat Ay 厄	, Barry

25 submissions were made total for the second challenge

- Ist Place: <u>Team from University of Minnesota</u>, achieving superior predictions in tasks 1.2 (r = 0.7, p-value = 0.001) and 2.1 (r = 0.81, p-value = 0.0031)
- 2nd Place: Team from LJI (Teams 54 and 38) ranked second overall.
- **3rd Place:** Team from National Institutes of Health (Team 51) ranked third overall and achieved the top rank for task 2.2

C. Winning model from 2nd Challenge





From University of Minnesota Group (Saonli Basu & Team) Dimension reduction through Multiple Co-inertia analysis and modeled with Linear mixed effect

D. Models from Second (invited) challenge



Debrief session where top 3 winners from the 2nd Challenge presented on Zoom:



Recording and slides Can be found on our discourse here: <u>https://discuss.cmi-pb.org/c/2nd-challenge/20</u>

e. Establishing baseline response of task variables to predict post-vaccination response



- **Goal:** Illustrate the processes of data access, model building, and model submissions for users.
- Datasets used:
 - Training dataset (2020 + 2021+ 2022)
- We calculated the Spearman correlation using the baseline and response values of the task variable.
 - For instance, we used the values of CCL3 from
 Day 0 to predict the response on Day 3.

Corr(CCL3_D0, CCL3_D3)



The correlation plot is generated by the training dataset.



Presentation Agenda



Summary of other resources on the site





CMI-PB Solutions Center

https://discuss.cmi-pb.org/

CMI-PB SOLUTIO	NS CENTER			୍ 🔹
Welcome to the Solutions Cente Browse the categories below	CMI-PB pr! or create an account to post.	← back to the site	iearn about the challenge	× contact us
≋ Topics ● ≗ My Posts	all categories all tags Cat	tegories Latest		+ New Category + New Topic
■ Review	-	-2		
Admin	: () }			25
Categories 1st (Internal) Challenge 2nd (Invited Participant • I General/Uncategorized : All categories	3rd (Public) Challenge Please use this page to discuss questions/issues about the 3rd (Public) CMI-PB challenge.	2nd (Invited Participants) Challenge Please use this page to discus: questions/issues about the 2nd CMI-PB challenge.	Site Feedback Discussion about this site, its organization, how it works, and how we can improve it.	Staff Private category for staff discussions. Topics are only visible to admins and moderators.
Tags		-	How does the Le	gendPlex assav
other-discussions			avtaking concer	trations in place
website	A a to (last terms a l)	O		u auviis ili plasi
All tags	Challenge	General/Uncategor Please use this page to di general questions/issue	Srd (Public) Challenge data-or	ganization 🔳 other-discussions 着
Messages	questions/issues about the 1st	regards to the CMI-PB co	Pramod D	
a Inbox a admins	CMI-PB challenge.		The CMI-PB team initia after the targeted cytol Legendplex assay for r	ally measured cytokine conce kine panel from Olink was diso measuring cytokine concentra



- Platform for knowledge sharing • and discussion
- An account is required to post or ulletrespond to threads

ompare to the Olink assay for measuring ? /

Willemsen

Pramod 🛡	15d	æ
The CMI-PB team initially measured cytokine concentrations in plasma using the Olink assay. Howe	ver,	Aug 12
after the targeted cytokine panel from Olink was discontinued in 2024, we transitioned to using the		1/2
Legendplex assay for measuring cytokine concentrations in plasma. Cytokine concentrations were		Aug 12
measured using Olink for the complete cohorts of 2020, 2021, and 2022, as well as for the partial co	hort	
of 2023. In contrast, cytokine concentrations were measured using Legendplex for the complete coh	orts	
of 2021, 2022, and 2023, with the exception of the 2020 cohort. Although predicting cytokine		
measurements is not a specific task in the CMI-PB public challenge, these measurements may play	а	
significant role in predicting outcomes involving different assays in other tasks.		
	Pramod The CMI-PB team initially measured cytokine concentrations in plasma using the Olink assay. Howe after the targeted cytokine panel from Olink was discontinued in 2024, we transitioned to using the Legendplex assay for measuring cytokine concentrations in plasma. Cytokine concentrations were measured using Olink for the complete cohorts of 2020, 2021, and 2022, as well as for the partial co of 2023. In contrast, cytokine concentrations were measured using Legendplex for the complete coho of 2021, 2022, and 2023, with the exception of the 2020 cohort. Although predicting cytokine measurements is not a specific task in the CMI-PB public challenge, these measurements may play significant role in predicting outcomes involving different assays in other tasks.	Pramod ♥ 15d The CMI-PB team initially measured cytokine concentrations in plasma using the Olink assay. However, after the targeted cytokine panel from Olink was discontinued in 2024, we transitioned to using the Legendplex assay for measuring cytokine concentrations in plasma. Cytokine concentrations were measured using Olink for the complete cohorts of 2020, 2021, and 2022, as well as for the partial cohort of 2023. In contrast, cytokine concentrations were measured using Legendplex for the complete cohorts of 2021, 2022, and 2023, with the exception of the 2020 cohort. Although predicting cytokine measurements is not a specific task in the CMI-PB public challenge, these measurements may play a significant role in predicting outcomes involving different assays in other tasks.

Creating an account

	CMI-PB Ab titer	v	Sign in to CMI-PB		CMI-PB SOLUTIONS CENTER	R
The missi	COMPUTATIONAL MODEL OF MANANTY PERTUSSIS BOOST	unity with a comprehensive, high-quality and f	reely accessible resource of Pertussis booster vaccination.		Welcome to CMI-PB SOLUTIO An account is required. Please create an account	NS CENTER t or log in to continue.
	LEARN ABOUT THE PROJECT	UNDERSTAND THE DATA	ACCESS THE DATA		Sign Up 💄 Log In	
			(N)		Step #2: Click "Sign Up" to cr	eate a new account
	The NIH funded CMI network What is pertussis vaccination?	How do we measure immune responses?	Data statistics Use the API in your programs		П	
Step #1	L: Click "Sign in t	o CMI-PB" in the	upper right hand corner		~*	
	CMI-PB Ab tite		cmi-pb-contest@lji.org <u>Submit prediction</u> \$ gn	Out	Welcome! Solution	
	PERTUSSIS BOOST				unique, no spaces, short	G with Google
The mission	n of CMI-PB is to provide the scientific co	nmunity with a comprehensive, high-qual	ity and freely accessible resource of Pertussis booster vaccinat	tion.	Vame your full name (optional)	
	LEARN ABOUT THE PROJECT	UNDERSTAND THE DATA	ACCESS THE DATA		Password	
	[(rel lign)		at least 10 characters Create your account Log In	
Step #4	Confirm that wh: in the	nen you are signe upper right hand	d in, your email is shown corner		By registering, you agree to the privacy policy and terms of service.	
					Step #3: Fill out registration for	orm or use <u>SSO with</u>
					<u>Google</u>	

ОСМІ-РВ НОМЕ РАGE

Creating a submission





Step #2: Follow all steps, click the "Choose File" button, and make your submission



The CMI-PB team





And thank you to the Sette Lab, Crotty lab, LJI Clinical Core, LJI Bioinformatics Core

The CMI-PB team members





Bjoern Peters



Steven Kleinstein



Ferhat Ay



Barry Grant



Alessandro Sette



Pramod Shinde



Shelby Orfield





Leying Guan



Joaquin Reyna



Mari Kojima



Jason Greenbaum



Brendan Ha



Aaron Ren



Ricardo De Silva Antunes



Jeremy Gygi



Anna Konstorum

Lisa Willemsen







Presentation Agenda





Questions?

Please post your questions on <u>https://discuss.cmi-pb.org/</u> under the 3rd Public Challenge



We will be hosting an open office hour session via Zoom on Monday, September 9th 11:30am-12:30pm PT/2:30pm-3:30pm ET.

Feel free to drop by if you have any questions! Zoom information is available on the Solutions Center <u>here</u>.